JP Morgan H&Q Healthcare Conference to Webcast the Medicines Company's Corporate Presentation
CAMBRIDGE, Mass.--(BW HealthWire)--Jan. 8, 2002--The Medicines Company (NASDAQ: MDCO - news) announced today that its new corporate presentation will be webcast live on Wednesday, January 9, 2002 at 11:00am ET (8:00am PT). The webcast may be viewed live at The Medicines Company's homepage, www.themedicinescompany.com and will be archived for 60 days.
Clive Meanwell, M.D., Ph.D., Executive Chairman, and Dave Stack, President and CEO will present an overview of the company at 11:00am ET (8:00am PT) on Wednesday, January 9, 2002 from the Westin St. Francis Hotel in San Francisco, California.
The Medicines Company was founded in 1996 to acquire, develop and commercialize selected pharmaceutical products in late stages of development and approved products. In December 2000, the Company received marketing approval from the U.S. Food and Drug Administration for ANGIOMAX® (bivalirudin) for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing coronary balloon angioplasty. The Company began selling ANGIOMAX in the United States in January 2001. The Company expects ANGIOMAX to be the cornerstone product of a planned acute hospital franchise. The Company is also developing a second product, CTV-05, a proprietary biotherapeutic agent with a potentially broad range of applications in the treatment of gynecological and reproductive infections. Additional information about the company and its products can be found at www.themedicinescompany.com.
This press release contains forward-looking statements that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words, ``believes,'' ``anticipates,'' ``plans,'' ``expects,'' ``intends,'' and similar expressions are intended to identify forward-looking statements. Important factors that could cause actual results to differ materially from the expectations described in these forward-looking statements are set forth under the caption ``Certain Factors that May Affect Future Results'' in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2001 and incorporated herein by reference. These risk factors include risks as to the commercial success of ANGIOMAX; how long the Company will be able to operate on its existing capital resources; whether the Company's products (other than ANGIOMAX for its approved indication) will advance in the clinical trials process, the timing of such clinical trials, whether the clinical trial results will warrant continued product development, whether and when, if at all, the Company's products will receive approval from the U.S. Food and Drug Administration or equivalent regulatory agencies, and for which indications, and, if such products receive approval, whether they will be successfully marketed; the Company's history of net losses; and the Company's dependence on third parties, including manufacturers, suppliers and collaborators. We do not assume any obligation to update any forward-looking statements.
--------------------------------------------------------------------------------
Contact:
The Medicines Company
Peyton Marshall, (617) 225-9099
or
The Medicines Company
Jill Sawdon, (617) 225-9099 |
